---
# System prepended metadata

title: Untitled

---

Global Influenza Diagnostics Market | Research, Analysis, Size, Share Growth And Forecast Report to 2028

 
![](https://i.imgur.com/rQR9xBi.jpg)


The Global Influenza Diagnostics Market size was valued at USD 0.75 Billion in 2021, and it is expected to reach a value of USD 1.2 Billion by 2028, at a CAGR of 6.89% over the forecast period (2022 - 2028).
Influenza is simply referred to as the flu. It is an infectious disease of the upper respiratory tract caused by the influenza virus. The seasonal influenza virus is classified into three types: Influenza B, Influenza A, And Influenza C, which are characterized by two major surface proteins: hemagglutinin (HA) and neuraminidase (NA). Different serotypes are observed as a result of differences in these surface proteins, which determine the antibody response to the viruses. Because influenza is a highly contagious and communicable disease, infected patients who serve as carriers of the disease can easily transmit the disease in public places.

Get more details about report : https://skyquestt.com/report/influenza-diagnostics-market 

Global Influenza Diagnostics Market Segmental Analysis
The Global Influenza Diagnostics Market is segmented based on Test Type, End-User, and Region. Based on Test Type it is categorized into Traditional Diagnostic Test and Molecular Diagnostic Assay. The Traditional Diagnostic Test segment is further bifurcated into RIDT, Viral Culture, Direct Fluorescent Antibody (DFA) Test, and Serological Assay. Molecular Diagnostic Assay is sub-segmented into RT-PCR, Nucleic Acid Sequence-based Amplification (NASBA) Test, Loop-mediated Isothermal Amplification-based Assay (LAMP), Simple Amplification-based Assay (SAMBA), and Other Molecular Diagnostic Assays. By End User, the Influenza Diagnostics Market studied is segmented into hospitals, Laboratories, and Other End Users. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.
Global Influenza Diagnostics Market Competitive Landscape
The Influenza Diagnostics Market is highly competitive, with the existence of numerous major firms operating in both domestic and international markets. The industry's top players are embracing strategic collaboration initiatives to improve market share and profitability. Some of the major players in the market are Becton Dickinson, Biomerieux, Merck, and Bio-Rad Laboratories among others who are driving the Influenza Diagnostics Market.

Top Player’s Company Profiles
•	Danaher Corporation (US)
•	Siemens Healthineers (Germany)
•	Thermo Fisher Scientific, Inc. (US)
•	F. Hoffmann-LA Roche AG (Switzerland)
•	Abbott Laboratories, Inc. (US)
•	Hologic, Inc. (US)
•	BioMérieux SA (France)
•	Quidel Corporation (US)
•	Becton, Dickinson, and Company (US)
•	Meridian Bioscience (US)
•	GenMark Diagnostics, Inc. (US)
•	Luminex Corporation (US)
•	Tecan Trading AG (Switzerland)
•	DiaSorin SA (Italy)
•	Altona Diagnostics GmbH (Germany)

Recent Developments
•	In May 2022, The American pharmaceutical company announced that it has obtained Nod from the USFDA for the drug Aptima CMV Quant Assay for human cytomegalovirus. Use. And this could be a great development in reducing the adverse effect of the virus on humans.
•	In February 2022, Siemens Healthineers, in partnership with United Nations Children's Fund, today announced its contribution to strengthening health systems in the various African region by improving access to diagnostics and the link to treatment of major diseases.
•	In September 2021, Simplexa COVID-19 & Flu A/B Direct kit from DiaSorin Molecular LLC received the CE mark. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, and influenza B virus from the same patient sample in a single reaction well.

Get free sample PFD Report copy at : https://skyquestt.com/sample-request/influenza-diagnostics-market 

Global Influenza Diagnostics Key Market Trends
•	Vaccination is a major method of immunizing individuals against infectious diseases to avoid serious complications, particularly in immunocompromised patients who are at high risk. Mutation of the virus serotype proves to be a major impediment because vaccination becomes difficult in such cases, putting the individual at risk of contracting the virus. Thus, as virus types change, it is critical to detect their presence in patients and administer timely medication to prevent fatalities. As a result, the demand for influenza diagnostics products has increased, accelerating market growth.
•	The rising geriatric population, broadening government anti-influenza initiatives, rising prevalence of chronic diseases such as diabetes, heart and blood disorders, and the emergence of technologically advanced influenza diagnostic tests are some of the key factors driving the influenza diagnostics market's growth.
•	Pregnant women, children, the elderly, immunocompromised patients with chronic medical conditions, and healthcare workers are at high risk of contracting influenza. The treatment for influenza consists of a variety of antiviral drugs that help to reduce complications and fatalities such as death. Antiviral drugs used conventionally are ineffective in the majority of patients due to drug resistance. As a result, the development of vaccines and drugs has seen an increase in demand, assisting developers in the industry.

